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The aim of this study was to evaluate with a long follow-up the efficacy of concomitant chemoradiotherapy in non-metastatic
inflammatory breast cancer (IBC) and to evaluate the breast conservation rate. Between 1990 and 2000, 66 non-metastatic patients
with IBC were treated with chemotherapy and concomitant irradiation. The induction chemotherapy consisted of epirubicine,
cyclophosphamide and vindesine, in association with split-course bi-fractionated irradiation to a total dose of 65Gy with concomitant
cisplatin and 5-fluorouracil. Maintenance chemotherapy consisted of high-dose methotrexate and six cycles of epirubicine,
cyclophosphamide and fluorouracil. Hormonal treatment was given if indicated. Mastectomy was not systemic. Among 65 evaluable
patients, 57 (87.6%) achieved a complete clinical response and had a breast conservation. Only six loco regional relapses were noted
in six patients with a delay of 20 months and with concomitant metastatic dissemination in four cases. Median disease-free survival
(DFS) was 28 months. Median overall survival (OS) was 63 months and median follow-up was 55.5 months. Induction chemotherapy
and concomitant irradiation is feasible in patients with IBC, permitting a breast conservation with a high rate of local control with an
OS comparable to that of the best recent series.
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Inflammatory breast cancer (IBC) accounts for 1–6% of all
invasive breast tumours (Chang et al, 1998). Its incidence has
doubled over the last 20 years (Hance et al, 2005).
Despite advances in treatment with induction chemotherapy
regimens, disease-free survival (DFS) and overall survival (OS)
remain unsatisfactory with a 30–50% 5-year survival in the largest
studies (Anderson et al, 2003; Cristofanilli et al, 2003; Somlo et al,
2004; Lerebours et al, 2005). The role of surgery remains
controversial even though it is often used in protocols (Schafer
et al, 1987; De Boer et al, 2000). The achievement of pathologic
response to induction chemotherapy is an excellent indicator of
prolonged (DFS) and (OS) (Ueno et al, 1997). This is achieved in
less than 30% of patients (Chevallier et al, 1993).
Based on these results, we conducted a protocol combining the
most active drugs such as anthracycline with radiotherapy as the
major local treatment as the initial treatment without mastectomy.
We report the long-term efficacy of this protocol in 66 patients
with non-metastatic IBC.
MATERIALS AND METHODS
Between 1990 and 2000, 66 consecutive patients with non-
metastatic IBC received treatment. All the patients were examined
by a multidisciplinary team and gave their written informed
consent for participation. Eligibility included clinical and/or
pathological criteria for IBC as defined by Haagensen (Haagensen,
1971). Non-metastatic IBC was defined by negative thoraco-
abdominal scan and bone scan.
The protocol was described previously (Tubiana-Mathieu et al,
2001) as shown in Figure 1: three cycles with a 28-day delay
associated in day 1, epirubicine (E) (50mgm
2), cyclopho-
sphamide (C) (350mgm
2) and vindesine (V) (2mgm
2), and
CDDP (10mgm
2day
1), 5-FU (500mgm
2day
1) in days 15–20
concomitantly with bifractioned radiotherapy. After the first 24
patients, the doses of chemotherapy were increased as follows: C
500mgm
2, E 75mgm
2 and CDDP 20mgm
2 days 15–20.
Radiotherapy was performed as split course to a dose of 45Gy with
a twice daily schedule of 15Gy for each course in 10 fractions for 5
days (1.5Gy per fraction). The three series were performed from
day 15 to 20 of each induction course concomitantly with CDDP
and 5-FU. The volume included the whole breast by two tangential
portals and supra clavicular, internal mammary chain, and
eventually axillary lymph nodes by direct portal (axillary lymph
nodes were not radiated after axillary dissection).
All volumes were treated by a
60Co or six megavolt photon beam
except the internal mammary chain, which was treated by a mixed
50–60% beam with photon and electron beam of adequate energy.
A boost irradiation course was performed 8 days after the 3rd
series. Twenty-four to 26Gy (calculated as ICRU criteria) in 12–13
daily fractions schedule over 16–17 days were administered to the
entire breast, including the skin, but not the rib cage. This boost
course was given without chemotherapy.
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were given for the first 3 months because 30% of the initial 20
patients developed upper limb thrombophlebitis. All cycles were
supported by granulocyte colony stimulating factor given from day
3 to 9 of each cycle.
After the radio chemotherapy programme, patients received
three cycles of high-dose methotrexate (MTX) (1.5gm
2) every 15
days and six cycles of FEC 50 (5-FU 500mgm
2, E 50mgm
2 and
C 500mgm
2) every 21 days as maintenance chemotherapy.
Patients with ER and/or PR positive breast cancer received
hormonotherapy: tamoxifen 20mgday
1 for 5 years in pre- and
postmenopausal patients after the end of chemotherapy and with
analogue LH-RH in premenopausal patients.
The clinical response was evaluated after each cycle of the
induction treatment. Multiple breast biopsies were performed after
the induction from 1994.
Surgery (mastectomy or quadrantectomy) was performed only
in case of stable disease or partial clinical or pathologic response.
After completion of the treatment, patients underwent physical
examination at least once every 4 months for the first 2 years and
every 6 months for 5 years. A yearly mammogram was performed,
with bone scans and chest X-rays only according to symptoms.
STATISTICAL METHODS
The primary end point of this study was clinical tumour response
defined in 1990 as follows: a complete response (CR) was defined
as the complete disappearance of all clinical evidence of disease;
partial response (PR) corresponded to a greater than 50% decrease
in tumour area; no change (NC) was less change than partial
regression without progressive disease; and progressive disease
(PD) corresponded to 25% or more increase in tumour area or
increased nodal stage or both.
Pathological response was assessed by six true-cut biopsies
performed after chemoradiotherapy. Pathological response was
complete (pCR) with no residual tumour cell on all biopsies.
Overall survival and DFS were calculated from diagnosis to last
contact for living patients. Follow-up was calculated with the same
variables. Disease-free survival was defined as the time of any type
of recurrence or death of any cause. The standard Kaplan Meier
method was applied for survival analysis.
Toxicities of treatment were graded according to the WHO scale.
RESULTS
Patients’ characteristics
Median age was 48 years (25–70). Thirty-four were pre-
menopausal and 32 postmenopausal.
The initial biopsy of the breast and the skin performed in all
patients found 53 ductal, 11 lobular and two undifferentiated
carcinoma. Sixty-two had clinical IBC with dermal lymphatic
involvement in 43 patients. Four had occult disease, all with
dermal lymphatic involvement.
To limit the radiotherapy fields, an axillary surgery was
performed in the first 45 patients at the same time of indwelling
catheter placement. Nodes picking were performed in nine
patients, with 1–5 nodes being removed, and all were involved.
Thirty-six axillary dissections were performed, with a median of 15
nodes being removed (8–32); 84% showed 7 or more involved
nodes.
Hormone receptor status was known in 58 patients. Estrogen/
progesterone receptors were positive/positive in 19 patients,
negative/negative in 28, and positive/negative in 11.
Evaluation of response
The clinical response was evaluated in 65 patients; one was not
evaluated because of death from pulmonary embolism at day 15.
Fifty-seven patients (87.6%) achieved clinical CR, seven (11%) a
clinical PR, and one a progression disease on the skin.
CR was obtained after two courses in 13 patients (38%) and after
three courses in 44 patients (62%).
Pathological response was assessed in 25 patients: 22 had a
pathologic complete response (pCR).
Among the seven patients with a partial clinical response,
mastectomy was performed in five patients: in two patients, viable
cells were not found in the breast (these two patients had a long
time survival of 51 and 80 months without relapse) and in three
patients, tumour viable cells were found (two patients developed
metastasis and one had no relapse after surgery). For the other two
patients, mastectomy was not performed due to the dramatic
evolution: one developed brain metastases at 5 months and died at
7 months and the other after tumorectomy developed pulmonary
metastasis at 6 months and died at 16 months.
Evaluation of survival
The median follow-up of the 66 patients was 55.5 months (range
4–178) in all patients and 89 months (28–178) in surviving
patients.
Among the 66 patients, 37 deaths occurred. All but four were
related to breast cancer (the four non-related deaths were
pulmonary embolism at 3 months, acute lymphoblastic leukaemia
at 13 months, heart failure at 28 months and cirrhosis at 75
months). Median OS was 63 months and median DFS was 28
months. The 5- and 10-year OS were 50.3 and 38%, respectively
(Figures 2 and 3).
Pattern of failure
As shown in Table 1, six patients developed local recurrence after a
median delay of 20 months (range 7–42); two recurrences were
only local without any distant metastasis and were alive without
other recurrence at 56 and 89 months, and for the other four
patients, local recurrence was associated with metastatic evolution.
Five patients presented contralateral disease, with a median delay
of 26 months (range 6–50). Two of them were isolated and three in
association with distant metastasis. Thirty-six showed a systemic
D1 D15 D20 D1 D15 D20 D1 D15 D20 D28
CT1 CT-RT1 CT2 CT-RT2 CT3 CT-RT3 RT boost
Cyclophosphamide,
epirubicin,
vindesine
Bifractionated
radiotherapy
CDDP and 5 FU
concomittantly
Figure 1 Induction treatment protocol plan. Three Cycles with 28 days delay.
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contralateral recurrence), with a median delay of 19.5 months
(1–84). Sites of metastases were principally liver (19 patients),
bone (11 patients), lung (6 patients) and brain (6 patients).
Treatment toxicities
As shown in Tables 2A and 2B, the toxicity of chemotherapy
during the induction phase was mainly haematologic with grade
3–4 neutropaenia in 33 patients (50%) and febrile neutropaenia in
8 patients (12%) without septic death. Grade 3–4 thrombopaenia
occurred in 16 patients (24%) and grade 3–4 anaemia occurred in
three patients (5%). During the maintenance phase, grade 3–4
neutropaenia occurred in 13 patients and grade 3–4 thrombo-
paenia occurred in 2 patients. Thrombosis occurred in eight
patients (five cases occurred before the initiation of the treatment
with warfarin; despite this preventive measure, two further cases
occurred, one of which had the pulmonary embolism previously
cited while receiving warfarin and then heparin). Other toxicities:
two patients developed grade 3 serum transaminase elevation, two
had grade 2 paraesthesias induced by cisplatin and two had grade
3 mucositis.
Radiotherapy was well tolerated during induction phase. One
skin toxicity in an obese patient was noted with a local abscess 10
months after the end of treatment. In six patients, the principal
side effect was rib fractures that occurred with a median delay of
12 months after the treatment.
One cardiac injury-related death was noted 31 months after
diagnosis. The patient had been treated in childhood for an acute
lymphoblastic leukaemia but had a normal cardiac function before
breast cancer treatment.
Feasibility
Fifty-five (83%) patients received 100% of the induction doses, 47
(71%) patients received 100% of the MTX dose, and 47 (71%)
patients received 100% of the maintenance FEC 50 dose. Among
the 41 patients who received higher doses of chemotherapy, 35
(85%), 27 (65%) and 29 (70%), respectively, received 100% of
induction, MTX and maintenance doses. The dose of anthracycline
was never decreased. All patients received the protocol radiation
dose. The median duration of radiation therapy was 81 days (range
60–98), compared with 70 days as initially planned. The median
duration of treatment was 9 months (range 2–13).
DISCUSSION
This study, with a long follow-up of 55.5 months, had demon-
strated the role of intensive initial chemoradiotherapy to improve
local control in IBC and to avoid mastectomy with a long survival.
Our population included very homogeneous patients.
The best outcome for these patients classically uses a multi-
modality therapy, including neoadjuvant chemotherapy, surgery,
adjuvant chemotherapy, radiotherapy and endocrine therapy in
case of positive receptors.
Radiotherapy was the mainstay of care for IBC. In a trial
published in 1987, Schafer et al (1987) demonstrated that patients
treated with neoadjuvant chemotherapy, surgery and adjuvant
chemotherapy but without radiotherapy developed local recur-
rences 8–17 months after mastectomy. In the present trial, we used
an early split course twice daily radiation therapy in combination
with chemotherapy. The treatment with a bifractionated irradia-
tion technique, permitting the use of a condensed tissue frame,
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Figure 2 Disease-free survival for all patients.
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Figure 3 Overall Survival for all patients.
Table 1 Pattern of failure
Pattern of failure Number Median delay in months (range)
Local recurrence 6 20 (7–42)
Alone 2
With systemic recurrence 4
Controlateral disease 5 26 (6–50)
Alone 2
With systemic recurrence 3
Systemic recurrence 36 19.5 (1–84)
Table 2A Induction haematological toxicity (worst toxicity for any
course)
G III–IV (%)
Anaemia 3 (5%)
Neutropaenia 33 (50%)
Febrile neutropaenia 8 (12%)
Thrombocytopaenia 16 (24%)
Table 2B Induction non-haematological toxicity
Nausea vomiting 4 (3 G II, 1 G II)
Neuropathy 3 (G II)
Phlebitis 8
Mucositis 2 (G III)
Rib fracture 6
Serum transaminase 7 (3 G II, 4 G III)
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regeneration between irradiation treatments (Thames et al, 1983).
An early report of the MD Anderson Cancer Center suggested the
potential benefits of using hyperfractionated radiotherapy that
were confirmed in a later study (Barker et al, 1980; Liao et al,
2000). In a previous study, bifractionated irradiation was used
after three cycles of chemotherapy and gave a very good rate of
local control of 72% (Arriagada et al, 1990).
The timing of radiotherapy varied in the different studies:
current practices delivered radiotherapy after chemotherapy and
do not use it to obtain a rapid response rate.
In the literature, the role of surgery in IBC has been
controversial. In the only prospective randomised study comparing
surgery vs radiotherapy following neoadjuvant chemotherapy in 57
patients with IBC, Mourali et al (1993) did not find any significant
difference in DFS between the two groups. De Boer et al (2000)
didn’t find any difference in OS, DFS and disease-free relapse in a
retrospective comparison between two groups of IBC patients: one
treated by surgery and radiotherapy and the other by radiotherapy
alone after neoadjuvant chemotherapy. But patients with complete
clinical response were encouraged to have radiotherapy alone. In
the trial of MD Anderson (Fleming et al, 1997; Ueno et al, 1997) in
178 patients, the authors found that patients who had response to
induction chemotherapy benefited from the addition of mastect-
omy to chemotherapy and radiation. A recent retrospective analysis
of 485 IBC patients has suggested that mastectomy in association
with chemotherapy and radiotherapy seemed to enhance loco-
regional control with no impact on survival, but patients without
mastectomy had more extensive disease at presentation. In our
study with radio-chemotherapy, we achieved a high clinical control
rate without mastectomy (88%), which is confirmed by the long
follow-up of 55.5 months with only six local recurrences in patients
in complete clinical response (four with concomitant metastatic
evolution) occurring in a median delay of 20 months.
Many different regimens of chemotherapy have been used, but
anthracycline based chemotherapy remains the reference of
systemic treatment (Chevallier et al, 1993; Mourali et al, 1993;
Bauer et al, 1995).
In their retrospective study of 308 patients, Panades et al, 2005
found that a more intense chemotherapy regimen improved 10
years breast cancer specific survival. Other series have found no
improvement on outcome with intensification (Therasse et al,
2003). In our protocol, after 24 patients we intensified the dose of
induction chemotherapy as described, and no difference in local
response was found before and after this intensification. On the
other hand, we were unable to statistically assess the impact of
chemotherapy dose on survival. Methotrexate was used after
induction treatment for its good meningeal diffusion, but six brain
or meningitis metastases occurred. Likewise, the role of main-
tenance chemotherapy must be elucidated.
The published survival data were obtained in historic trials or in
retrospective studies based on single institution experience and
have reported that at least one-third of patients treated with multi
modality therapy are alive at 5 years. A recent report of the
National Cancer Institute based on epidemiologic survey between
1988–1990 and 1997–1999 showed a poor median survival in IBC
with 2.9 years (Hance et al, 2005). A larger retrospective trial
reports the experience of the MD Anderson Cancer Center with a
long follow-up of 7.4 years in 178 IBC patients treated with
different multimodality protocols during a 20-year period: the
median survival was 37 months for all patients. Overall survival at
5 and 10 years was 40 and 33%, respectively. Other studies
reporting a long follow-up for IBC achieved an OS at 5 years from
34 to 75% (Liao et al, 2000; Harris et al, 2003; Baldini et al, 2004;
Liauw et al, 2004), at 10 years range, respectively, from 13 to 47%
(Low et al, 2004; Cariati et al, 2005) and a median OS between 25 to
62 months.
Many questions are not resolved in IBC treatment, such as the
contribution of new drugs like Taxanes, the duration of
chemotherapy, the best local treatment and the role of new
molecular markers. However, the results obtained with initial dose
dense chemotherapy and concomitant irradiation permit the
proposal of this association as a useful therapeutic option.
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